Medtronic (MDT) Rises As Market Takes a Dip: Key Facts

Medtronic (MDT) shares advanced 2.1% to $91.24 in the latest session, significantly outperforming the S&P 500's daily loss of 0.08%. While the stock has gained 0.4% over the past month, surpassing its Medical sector, it underperformed the S&P 500. Investors are keenly awaiting the August 19, 2025 earnings report, where analysts project 5.73% revenue growth to $8.37 billion, though EPS is expected to remain flat at $1.23. Medtronic currently holds a Zacks Rank of #3 (Hold) and trades at a Forward P/E of 16.11, presenting a discount relative to its industry's 17.56.

Analysis

Medtronic (MDT) demonstrated notable relative strength in the last session, gaining 2.1% to close at $91.24 while the S&P 500 posted a daily loss of 0.08%. Over the past month, its 0.4% gain surpassed the Medical sector's 3.99% loss, though it underperformed the S&P 500's 1.21% advance. Investor focus is now on the upcoming earnings, where consensus estimates project a 5.73% year-over-year revenue increase to $8.37 billion, but with earnings per share expected to remain flat at $1.23. This suggests potential margin pressure, a theme that extends to the full-year forecast of 5.22% revenue growth translating to only 1.09% EPS growth. Analyst sentiment appears neutral to slightly negative, underscored by a Zacks Rank of #3 (Hold) and a minor 0.01% downward revision to the consensus EPS projection over the last 30 days. On a valuation basis, MDT's forward P/E of 16.11 presents a discount to its industry's average of 17.56, but its PEG ratio of 2.32 is slightly above the industry average of 2.19, indicating its price may be less attractive when factoring in its modest growth outlook. The stock also faces headwinds from its industry, which ranks in the bottom 37% of over 250 analyzed by Zacks.

Key Decisions for Investors

• Investors should weigh the stock's valuation discount, indicated by a forward P/E of 16.11, against its flat near-term earnings forecast and a PEG ratio of 2.32 that suggests limited upside relative to its growth prospects.
• Closely monitor the upcoming earnings report for commentary on margins, as projected revenue growth of over 5% is currently not expected to translate into bottom-line EPS growth.
• Consider that while MDT has shown recent relative strength against its sector, it operates within a weakly-ranked industry (bottom 37%) and has underperformed the broader market, which may present persistent headwinds.
• The neutral Zacks #3 (Hold) rating and recent downward revision in EPS estimates warrant a cautious approach, balancing the recent positive price momentum against lackluster fundamental growth forecasts.